Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Pi-Cardia ShortCut TAVR device

FDA clears new device for valve-in-valve TAVR patients at risk of coronary obstruction

ShortCut, which gained the FDA’s breakthrough device designation back in January, is used to split valve leaflets and reduce the risk of obstruction.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Reduced LVEF before TAVR linked to lower long-term survival rate

Heart teams already view reduced LVEF as a potential risk factor, but research into its long-term impact on patient outcomes has been limited. 

cardiologist viewing heart data

Long-term survival after valve-in-valve TAVR similar with self-expanding, balloon-expandable valves

Severe prosthesis-patient mismatch was more common with balloon-expandable valves, but that difference did not appear to impact outcomes. 

cardiologist patient heart compensation starting salary 2022 interventional cardiologist

LBBAP limits hospital readmissions after TAVR

Left bundle branch area pacing is associated with better long-term outcomes than traditional right ventricular pacing when patients require PPMI after TAVR, according to new research in Heart Rhythm. 

heart surgery surgeons

SAVR associated with several long-term benefits for patients with asymptomatic severe AS

The current evidence suggests early surgery is a better treatment option for asymptomatic severe AS than conservative care, researchers explained.

Balloon-expandable transcatheter aortic valve replacement (TAVR) valves that fail to expand symmetrically may be associated with worse hemodynamic data, according to a new analysis published in JACC: Cardiovascular Interventions.

Asymmetrical valve expansion after TAVR a cause for concern

Calcified debris can sometimes lead to stent frame issues that cause a patient's TAVR valve to expand asymmetrically. Few studies have explored the potential impact of valve asymmetry—until now. 

Royal Philips has received U.S. Food and Drug Administration (FDA) approval for its new 160-cm LumiGuide endovascular navigation wire, which uses the company’s popular Fiber Optic RealShape (FORS) technology to deliver real-time 3D visualization without the use of fluoroscopy.

FDA approves longer LumiGuide 3D navigation wire from Philips

The newly approved device comes in at 160 cm. Like the shorter LumiGuide device from Philips, it was designed to deliver real-time 3D visualization with light instead of X-rays. 

A demonstration of SenitAR's augmented reality (AR) technology for electrophysiology lab procedures during the Heart Rhythm Society 2024 meeting. This is one of at least six FDA-cleared clinical AR and virtual reality applications that aimed at enhancing cardiology workflow and patient outcomes. Photo by Dave Fornell

A glimpse into the future: FDA has cleared multiple AR, VR tools for cardiology

Heart teams already have access to several augmented reality and virtual reality offerings, and many more are on the way.

Displaying 49 - 56 of 874
Design by Adaptive Theme